Generation Bio Co
GBIO4.470USD
+0.260+6.18%
交易中 （美东）报价延迟15分钟
299.53M总市值
亏损市盈率 TTM
关于 Generation Bio Co 公司
Generation Bio Co. 是一家生物技术公司。该公司正在创新非病毒基因药物，为数亿患有罕见和流行疾病的患者提供持久、可重复使用的治疗方法。该公司正在开发两个独特且互补的平台：一种强效、高选择性的细胞靶向脂质纳米颗粒 (ctLNP) 递送系统和一种新型免疫静默 DNA (iqDNA) 货物，后者采用可扩展的无衣壳制造工艺生产，该工艺使用专有的无细胞快速酶合成 (RES)。该公司正在推进一系列项目，这些项目以强效和高选择性的信使核糖核酸 (mRNA) 和/或 iqDNA 递送为指导，使用其 ctLNP 递送系统靶向 T 细胞、造血干细胞 (HSC) 和肝细胞，并打算扩展到其他组织和细胞类型。其在 T 细胞方面的工作重点是体内重新编程这种细胞类型以治疗癌症和自身免疫性疾病。
公司简介
公司代码GBIO
公司名称Generation Bio Co
上市日期Jun 12, 2020
CEODr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
员工数量115
证券类型Ordinary Share
年结日Jun 12
公司地址301 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话18575295908
网址https://generationbio.com/
公司代码GBIO
上市日期Jun 12, 2020
CEODr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
185.48K
+0.20%
Dr. Anthony G. Quinn, M.D., Ph.D.
Dr. Anthony G. Quinn, M.D., Ph.D.
Independent Director
Independent Director
37.21K
--
Mr. Gustav A. Christensen
Mr. Gustav A. Christensen
Independent Director
Independent Director
13.14K
--
Dr. Phillip Samayoa, Ph.D.
Dr. Phillip Samayoa, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
12.93K
+0.63%
Ms. Yalonda Howze, J.D.
Ms. Yalonda Howze, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
6.70K
+3.67%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
4.75K
--
Ms. Dannielle Appelhans
Ms. Dannielle Appelhans
Independent Director
Independent Director
2.00K
+150.00%
Mr. Kevin John Conway
Mr. Kevin John Conway
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
1.83K
+2.35%
Mr. Ronald Harold Wilfred (Ron) Cooper
Mr. Ronald Harold Wilfred (Ron) Cooper
Independent Director
Independent Director
950.00
--
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
185.48K
+0.20%
Dr. Anthony G. Quinn, M.D., Ph.D.
Dr. Anthony G. Quinn, M.D., Ph.D.
Independent Director
Independent Director
37.21K
--
Mr. Gustav A. Christensen
Mr. Gustav A. Christensen
Independent Director
Independent Director
13.14K
--
Dr. Phillip Samayoa, Ph.D.
Dr. Phillip Samayoa, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
12.93K
+0.63%
Ms. Yalonda Howze, J.D.
Ms. Yalonda Howze, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
6.70K
+3.67%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
4.75K
--
收入明细
FY2024
FY2023
暂无数据
地区USD
名称
营收
占比
United States
19.89M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Associates, Inc.
13.25%
Atlas Venture
12.35%
Modernatx Inc
8.74%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
4.64%
Other
53.93%
持股股东
持股股东
占比
T. Rowe Price Associates, Inc.
13.25%
Atlas Venture
12.35%
Modernatx Inc
8.74%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
4.64%
Other
53.93%
股东类型
持股股东
占比
Investment Advisor
38.32%
Venture Capital
12.43%
Investment Advisor/Hedge Fund
9.30%
Corporation
8.74%
Hedge Fund
6.59%
Individual Investor
5.64%
Research Firm
5.05%
Family Office
0.13%
Bank and Trust
0.09%
Other
13.72%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
204
5.77M
86.15%
-1.71M
2025Q1
216
58.42M
87.25%
-16.87M
2024Q4
239
64.26M
96.22%
-10.38M
2024Q3
252
65.74M
98.51%
-9.46M
2024Q2
257
65.96M
99.11%
-9.63M
2024Q1
256
65.28M
99.25%
-2.56M
2023Q4
262
62.66M
95.79%
-3.14M
2023Q3
260
66.58M
101.93%
-550.54K
2023Q2
272
66.62M
102.34%
-297.13K
2023Q1
283
66.66M
111.77%
+650.55K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Associates, Inc.
8.88M
13.25%
-217.22K
-2.39%
Mar 31, 2025
Atlas Venture
8.28M
12.35%
--
--
Mar 31, 2025
Modernatx Inc
5.86M
8.74%
--
--
Apr 07, 2025
Fidelity Management & Research Company LLC
4.75M
7.09%
+126.37K
+2.73%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
4.64%
-49.92K
-1.58%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.97M
4.43%
-13.81K
-0.46%
Mar 31, 2025
The Vanguard Group, Inc.
2.62M
3.91%
-22.29K
-0.84%
Mar 31, 2025
Baker Bros. Advisors LP
1.94M
2.9%
--
--
Mar 31, 2025
Renaissance Technologies LLC
1.88M
2.81%
+917.71K
+95.30%
Mar 31, 2025
McDonough (Cameron Geoffrey)
1.85M
2.76%
+15.31K
+0.83%
Apr 15, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Proshares Ultra Russell 2000
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 ETF
0%
iShares Biotechnology ETF
0%
Avantis US Small Cap Equity ETF
0%
Fidelity Blue Chip Growth ETF
0%
Avantis US Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
查看更多
Proshares Ultra Russell 2000
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
iShares Micro-Cap ETF
占比0%
iShares Russell 2000 ETF
占比0%
iShares Biotechnology ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Fidelity Blue Chip Growth ETF
占比0%
Avantis US Equity ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Invesco RAFI US 1500 Small-Mid ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
